Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors

Table 2 Summary of treatment-related adverse events (TRAE) in all grades of severity

N (%)	Selinexor 60 mg QW/BIW + carboplatin 6 AUC Q3W (N = 6)		Selinexor 60 mg QW/BIW + doxorubicin 60 mg/m² + cyclophosphamide 600 mg/m² Q3W (N = 4)		Selinexor 40 mg QW + FOLFIRI^a (N = 3)		Selinexor 60 mg QW + irinotecan 125 mg/m² D1 and 8 Q3W (N = 3)		Selinexor 40 mg QW + XELOX^b (N = 3)		All patients (N = 19)
N (%)	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4
Anemia	5 (83)	2 (33)	2 (50)	0	1 (33)	0	1 (33)	0	1 (33)	1 (33)	10 (53)	3 (16)
Leukopenia	4 (75)	1 (17)	3 (75)	3 (75)	3 (100)	0	1 (33)	0	2 (67)	1 (33)	13 (68)	5 (26)
Neutropenia	4 (75)	2 (33)	3 (75)	3 (75)	2 (67)	1 (33)	2 (67)	1 (33)	1 (33)	1 (33)	12 (63)	8 (42)
Thrombocytopenia	6 (100)	3 (50)	3 (75)	0	2 (67)	0	2 (67)	0	3 (100)	0	16 (84)	3 (16)
Constipation	0	0	0	0	0	0	0	0	0	0	0	0
Diarrhea	2 (33)	0	0	0	0	0	1 (33)	0	1 (33)	1 (33)	4 (21)	1 (5)
Nausea	4 (75)	0	4 (100)	0	1 (33)	0	1 (33)	0	3 (100)	0	13 (68)	0
Vomiting	4 (75)	0	3 (75)	0	0	0	1 (33)	0	2 (67)	0	10 (53)	0
Elevated AST/ALT	0	0	0	0	1 (33)	0	1 (33)	0	0	0	2 (11)	0
Mucositis	0	0	0	0	0	0	0	0	0	0	0	0
Fatigue	4 (75)	0	2 (50)	0	1 (33)	0	3 (100)	1 (33)	1 (33)	0	11 (58)	1 (5)
Anorexia	1 (17)	0	0	0	0	0	1 (33)	0	2 (67)	0	4 (21)	0
Hyponatremia	3 (50)	2 (33)	0	0	1 (33)	1 (33)	1 (33)	0	1 (33)	1 (33)	6 (32)	4 (21)
Hypomagnesemia	1 (17)	0	0	0	0	0	0	0	1 (33)	0	2 (11)	0
Hypoalbuminemia	0	0	0	0	0	0	0	0	0	0	0	0
Dyspnea	0	0	0	0	0	0	0	0	1 (33)	0	1 (5)	0
Cough	0	0	0	0	0	0	0	0	0	0	0	0
Elevated CPK	1 (17)	0	0	0	0	0	0	0	0	0	1 (5)	0
Infection or infestation	0	0	0	0	0	0	0	0	0	0	0	0
Elevated lipase	1 (17)	1 (17)	0	0	0	0	0	0	0	0	1 (5)	1 (5)

^aFOLFIRI—irinotecan of 180 mg/m², 5-FU continuous infusion of 2400 mg/m², 5-FU bolus of 400 mg/m², and leucovorin of 400 mg/m² on days 1, and 15
^bXELOX—capecitabine was dosed at 900 mg/m² orally (PO) divided into 2 doses on days 1–14, along with oxaliplatin of 130 mg/m² IV Q3W
QW once weekly; BIW twice weekly; AUC area under curve; mg/m² milligrams per square meter; D1 and 8 on days 1, and 8 of each cycle; Q3W every 3 weeks; ALT alanine aminotransferase; AST aspartate aminotransferase; CPK creatine phosphokinase; FOLFIRI irinotecan with fluorouracil and folinic acid; 5-FU 5-fluorouracil; XELOX capecitabine and oxaliplatin

ISSN: 2162-3619